Janux Therapeutics Inc [JANX] stock is trading at $24.31, up 2.23%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The JANX shares have gain 5.51% over the last week, with a monthly amount glided 7.23%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Janux Therapeutics Inc [NASDAQ: JANX] stock has seen the most recent analyst activity on September 10, 2025, when Truist initiated its Buy rating and assigned the stock a price target of $100. Previously, Stifel started tracking the stock with Buy rating on September 10, 2025, and set its price target to $45. On September 04, 2025, Guggenheim initiated with a Buy rating and assigned a price target of $72 on the stock. Piper Sandler started tracking the stock assigning a Overweight rating and suggested a price target of $42 on August 19, 2025. Raymond James initiated its recommendation with a Outperform and recommended $65 as its price target on July 11, 2025. H.C. Wainwright reiterated a Buy rating for this stock on December 03, 2024, and upped its price target to $70. In a note dated December 03, 2024, BTIG Research reiterated an Buy rating on this stock and boosted its target price from $82 to $100.
Janux Therapeutics Inc [JANX] stock has fluctuated between $21.97 and $71.71 over the past year. Currently, Wall Street analysts expect the stock to reach $68.5 within the next 12 months. Janux Therapeutics Inc [NASDAQ: JANX] shares were valued at $24.31 at the most recent close of the market. An investor can expect a potential return of 181.78% based on the average JANX price forecast.
Analyzing the JANX fundamentals
Janux Therapeutics Inc [NASDAQ:JANX] reported sales of 0.44M for the trailing twelve months, which represents a drop of -100.00%. Gross Profit Margin for this corporation currently stands at 1.26% with Operating Profit Margin at 17.95%, Pretax Profit Margin comes in at 13.09%, and Net Profit Margin reading is 13.09%. To continue investigating profitability, this company’s Return on Assets is posted at -0.1, Equity is -0.11 and Total Capital is -0.14. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 23.58 points at the first support level, and at 22.86 for the second support level. However, for the 1st resistance point, the stock is sitting at 25.19, and for the 2nd resistance point, it is at 26.08.
Ratios To Look Out For
For context, Janux Therapeutics Inc’s Current Ratio is 47.03. Further, the Quick Ratio stands at 47.03, while the Cash Ratio is 2.45. Considering the valuation of this stock, the price to sales ratio is 3320.18, the price to book ratio is 1.46.
Transactions by insiders
Recent insider trading involved Meyer Andrew Hollman, Chief Business Officer, that happened on May 01 ’25 when 3333.0 shares were sold. Officer, ANDREW MEYER completed a deal on May 01 ’25 to buy 3333.0 shares. Meanwhile, Chief Business Officer Meyer Andrew Hollman sold 3334.0 shares on Apr 21 ’25.
